Nanatinostat

    WARNING: This product is for research use only, not for human or veterinary use.

Description: Nanatinostat, also known as Tractinostat, CHR-3996 and VRx-3996, is an orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.

Price and Availability

Nanatinostat is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: CHR3996; CHR-3996; CHR 3996; VRx-3996; VRx3996; VRx 3996; Nanatinostat; Tractinostat;

IUPAC/Chemical Name: 2-(6-(((6-fluoroquinolin-2-yl)methyl)amino)bicyclo[3.1.0]hexan-3-yl)-N-hydroxypyrimidine-5-carboxamide

InChi Key: YUARZLJFVKGLFC-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H20FN5O2/c22-14-2-4-18-11(5-14)1-3-15(26-18)10-23-19-16-6-12(7-17(16)19)20-24-8-13(9-25-20)21(28)27-29/h1-5,8-9,12,16-17,19,23,29H,6-7,10H2,(H,27,28)

SMILES Code: O=C(C1=CN=C(C2CC3C(NCC4=NC5=CC=C(F)C=C5C=C4)C3C2)N=C1)NO

Technical Data

Additional Information

CHR-3996 is an optimised HDAC Inhibitor for Treatment of Cancers. Histone Deacetylases (HDACs) are a family of metalloenzymes that are able to Deacetylase Histones, leading to repression of gene expression. Inhibition of HDACs has been shown to impact multiple aspects of tumour progression. First generation HDAC inhibitors have demonstrated the clinical utility of this class, but in many cases lack optimal pharmaceutical characteristics. CHR-3996 is a potent, orally-active, pharmaceutically optimised class I HDAC selective inhibitor. CHR-3996 was entered into clinical development in 2008.  (source: http://www.chromatherapeutics.com/CHR-3996.htm).
 
 
 

References

1: Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, Wibawa J, Brotherton D, Stimson L, Clark V, Owen J, Bawden L, Box G, Bone E, Mortenson P, Hardcastle A, van Meurs S, Eccles S, Raynaud F, Aherne W. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrim idine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010 Dec 23;53(24):8663-78. Epub 2010 Nov 16.  PubMed PMID: 21080647.